X0306 4 2021-12-02 false 0001636422 Health Catalyst, Inc. HCAT 0001855244 Hinton Bryan Richard C/O HEALTH CATALYST, INC. 10897 SOUTH RIVER FRONT PARKWAY, #300 SOUTH JORDAN UT 84095 false true false false Chief Technology Officer Common Stock 2021-12-02 4 F false 2918.00 41.9475 D 15832.00 D Common Stock 2021-12-03 4 M false 105.00 10.78 A 15937.00 D Common Stock 2021-12-03 4 S false 105.00 42.87 D 15832.00 D Common Stock 2021-12-06 4 S false 1400.00 37.6946 D 14432.00 D Common Stock 2021-12-06 4 S false 5057.00 38.6388 D 9375.00 D Stock Option (Right to Buy) 10.78 2021-12-03 4 M false 105.00 10.78 D 2028-05-03 Common Stock 105.00 529.00 D Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Represents a weighted average price reported by the broker. These shares were sold as part of a block trade in multiple transactions at prices ranging from $40.33 to $42.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote with regard to the block trade. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on June 3, 2021, in accordance with Rule 10b5-1. Represents the weighted average sale price of the shares sold ranging from $37.35 to $38.21 per share, inclusive. Represents the weighted average sale price of the shares sold ranging from $38.37 to $39.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (4) and (5). 25% of the 5,082 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on May 3, 2022. /s/ Daniel Orenstein, as Attorney-in-Fact 2021-12-07